Online inquiry

IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10760MR)

This product GTTS-WQ10760MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ADAMTSL5&ALB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Lama glama; Humanized
RefSeq NM_213604.3; NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 339366; 213
UniProt ID Q6ZMM2; P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10760MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ761MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ13256MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ14534MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ4682MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ4283MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ12101MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ14145MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ8575MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Hu5F9-G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW